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Abstract
Objectives: Pancreatic leak is a morbid complication following left pancreatectomy, which results in
prolonged hospitalization, additional diagnostic testing and invasive procedures. The present authors
have previously demonstrated that mesh reinforcement of stapled left pancreatectomy results in fewer
pancreatic leaks. This study was conducted to investigate whether mesh reinforcement also results in
cost benefits for the health care system.
Methods: A cost benefit model was developed to estimate net cost savings from the payer's perspec-
tive. The model is based on the results of a randomized, single-blinded trial of mesh versus no mesh
reinforcement of the pancreatic remnant after left pancreatectomy. A two-way sensitivity analysis was
conducted to determine the model's sensitivity to fluctuations in the cost of mesh and the effectiveness
of the mesh in reducing clinically significant leaks.
Results: Average total costs for an episode of care were US$13 337 and US$15 505 for patients who did
and did not receive mesh, respectively, which indicates savings of US$2168. Two-way sensitivity analysis
showed that, given a probability of 1.9% for developing a clinically significant leak in patients in whom
mesh reinforcement was used, the strategy would continue to save costs if mesh were priced at
US$1804.
Conclusions: Mesh reinforcement decreases clinically significant pancreatic leaks. Despite the addi-
tional cost of mesh reinforcement, the use of mesh reinforcement results in overall cost savings for the
health care system because of the resultant decrease in the occurrence of clinically significant leaks.
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Introduction
Pancreatectomy is performed to excise known malignancy,
prevent malignant transformation or relieve symptoms. Left pan-
createctomy (resection of the pancreas left of the superior
mesenteric vein), whether performed via an open or a laparo-
scopic technique, is frequently associated with complications
caused by the postoperative leakage of pancreatic fluid from the
occluded stump of the pancreas (pancreatic leak). Although pan-
creatic leak may be asymptomatic in a minority of patients, it
more often leads to morbid complications and alters patient care.
As a result, pancreatic leak is one of the most intensely studied
surgical complications.1–3 The reported rates and definitions of
pancreatic leak have varied widely in the past. The recent consen-
sus conference and standardization of a classification schema have
helped to facilitate comparisons among data from different stud-
ies.4 The best estimate of the magnitude of the current problem is
from prospective studies which use the modern consensus defini-
tion and focus on pancreatic leak as the principle endpoint. The
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largest of these is the DISPACT cooperative trial, which compared
stapling and hand-sewing techniques for closure of the pancreatic
remnant.5 This showed no significant difference in leak rates
between hand-sewn (28%) and stapled (32%) closures, but, more
importantly, demonstrated that this problem remains an impor-
tant challenge.6 Clinically significant pancreatic leaks burden
patients adversely, as can be gauged by increases in hospital stay,
rates of readmission, and requirements for additional interven-
tional and diagnostic procedures, and intensive care unit (ICU)
transfers. Retrospective analyses have demonstrated that this com-
plication translates into increased health care costs for patients
amounting to tens of thousands of dollars.7
In an effort to understand and reduce the rate of pancreatic
leak, the present group performed a single-blinded randomized
controlled trial (RCT) of mesh reinforcement for stapled left pan-
createctomy in both laparoscopic and open procedures.8 Com-
plete details on this trial were published in 2012,8 but are briefly
summarized here. The mesh reinforcement group showed a
reduction in the planned primary endpoint of clinically signifi-
cant leaks categorized as Grade B and C leaks according to the
International Study Group on Pancreatic Fistula (ISGPF) classifi-
cation system. Rates of clinically significant leak (Grades B and C)
were 24.4% (11 of 45 patients) in the control group and 1.9% (one
of 53 patients) in the mesh reinforcement group (P = 0.0007). The
patients in this trial serve as a basis for the cost benefit model
explored here. If all grades of leak (Grades A, B and C) were to be
included in the model, no difference would be seen in this cost
model because by definition Grade A leaks cannot result in a
change in clinical management and therefore cannot incur costs.
Leaks originally coded as Grade A leaks which eventually incurred
costs are upgraded to the appropriate B or C category. The present
authors hypothesized that the observed reduction in the fre-
quency of clinically significant pancreatic leak would provide sig-
nificant benefit to patients and hence result in cost savings for the
health care system. However, not all patients develop clinically
significant pancreatic leaks and only a limited number of patients
would benefit from this intervention. The objective of this study
was to determine if the additional cost of using mesh in all
patients undergoing stapled left pancreatectomy would justify the
benefit gained and hence result in overall cost savings for the
health care system.
Materials and methods
An evaluation of the use of mesh reinforcement in patients under-
going left pancreatectomy was conducted. This employed a simple
decision model and took a cost benefit approach from the payer’s
perspective.
The randomized clinical trial was approved by the internal
review board of the Washington University School of Medicine
and registered on clinicaltrials.gov (NCT01359410). The study
began on 1 July 2007 and ended on 30 November 2010. The study
was stopped ahead of full recruitment because it met early stop-
ping criteria at interim analysis.8
Model construction
A simple decision model was constructed comparing two simu-
lated cohorts of patients undergoing left pancreatectomy with or
without mesh reinforcement (Fig. 1). The model replicated the
post-surgical experience of patients for 100 days following index
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Figure 1 Decision model constructed to compare two simulated cohorts of patients undergoing left pancreatectomy with and without mesh
reinforcement, respectively
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surgery. Costs considered in the model include initial surgical
costs (hospital and physician fees for surgery and the cost of mesh
reinforcement) and potential post-surgical costs of care, including
but not limited to costs of hospital and physician fees, subsequent
drain replacement and cross-sectional imaging. The result of the
model is the expected total net cost of the post-surgical manage-
ment of a patient who underwent surgical extirpation. The statis-
tical result of the model represents the net benefit of the
management strategy; the strategy that results in the lowest net
cost is considered to provide the highest net benefit to the payer.
The model was constructed and evaluated using TreeAge 2011
(TreeAge Software, Inc., Williamsport, MA, USA), a software spe-
cifically designed to create and evaluate decision trees and
models.9
The design incorporates important cost determinants derived
from the present group’s recent randomized clinical trial.8 Each
patient’s perioperative history was known as these data points
were collected as secondary endpoints in the clinical trial. In addi-
tion, the hospital provided data on all captured billing events for
100 days following the surgery date, including initial length of stay
and emergency room visits, radiologic tests, admissions to and
duration of any ICU stay, and interventional procedures. This
incomplete list gives examples of the types of event captured but
is not inclusive of all data in the paper. A few patients incurred
billing events at outside hospitals in the surrounding area. Patients
who were admitted to outside facilities were included in the
present model and it is likely that all events at outside hospitals
were captured in this trial. The Medicare cost estimates used for
the cost benefit model were identical to those used for events at
the primary study institution. These events were added together
with events at Barnes–Jewish Hospital (St Louis, MO, USA) to
determine estimates of total health care utilization.
As is consistent with the recommendations of the Panel on
Cost-effectiveness in Health and Medicine, US Public Health
Service, the costs of procedures from the payer’s perspective,
including both physician and hospital charges, were estimated
according to the 2012 Medicare allowable charges.10 It was
assumed mesh reinforcement was reimbursable by the payer at a
fixed cost of US$165 for mesh per procedure (the average cost of
mesh at the study institution during the trial). Other costs were
based upon expert opinion; when such opinion was used, the
influence of these assumptions on the decision was tested in sen-
sitivity analyses.
Sensitivity analysis
The robustness of the cost benefit decision to assumptions con-
cerning parameter values was evaluated using one-way sensitivity
analysis.11 Given uncertainty in model parameters, a two-way sen-
sitivity analysis was conducted to determine the model’s sensitiv-
ity to fluctuations in the cost of mesh and the effectiveness of the
mesh in reducing the occurrence of clinically significant leaks.
Variables that change the cost benefit decision are reported.
Results
Utilizing the decisionmodel (Fig. 1) and the clinical outcome data,
patients were assigned to each limb of the decisionmodel. Costs to
the health care system were determined for each patient and
assigned to the respective group.Average costs were determined for
each breakpoint along each respective limb of the decision model.
Table 1 lists the probabilities used for the cost benefit and sen-
sitivity analyses of themodel. Probabilities were obtained from the
results of the trial. Model probabilities for each group (no mesh
reinforcement versus mesh reinforcement) include those for the
following categories: any leak; clinically significant leak; upgrade
in leak status, and replacement of drain. ‘Any leak’ includes all
leaks (i.e. both clinically relevant ISGPF Grade B or C leaks and
clinically asymptomatic ISGPF Grade A leaks). Clinically signifi-
cant leaks include only leaks of Grades B and C. The upgrade leak
category was necessary to capture Grade A leaks that became
Grade B or C leaks. This occurred in several patients. For example,
this type of event occurred when a drain capturing a Grade A leak
became accidently dislodged and a new drain was required. As
need for an interventional procedure is one of the defining factors
in determining leak grade, this category of upgrade leak was
helpful in determining cost analysis.
Table 2 presents cost estimates for significant patient events in
2012 Medicare dollars. These are the costs utilized for the subse-
quent sensitivity analysis. Costs were determined utilizing the
Medicare database and published data on specific institutional
costs. Costs varied slightly over the duration of the trial, but for
modelling purposes all monetary values of earlier events were
adjusted for inflation to 2010 US dollars using the Consumer Price
Index for medical care (derived from the US Bureau of Labor
Statistics).
The probabilities of events in Table 1 were combined with the
cost data in Table 2 to determine that the expected cost of post-
Table 1 List of probabilities used in the model
Probability Baseline
(no mesh)
Mesh
reinforcement
Reduction (baseline –
with mesh)
Any leak 56.5% 38.4% 17.6%
Clinically significant leak 23.8% 1.9% 22.0%
Upgrade leak status 7.7% 0.0% 7.7%
Replace drain 23.8% 1.9% 22.1%
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operative management of a patient who underwent left pancrea-
tectomy was US$13 337 if mesh was placed intraoperatively and
US$15 505 if no mesh was used. This indicates that, on average,
the use of mesh resulted in a saving of US$2168 per patient (from
the payer’s perspective).
One-way sensitivity analysis (Fig. 2) showed that at a mesh
price of US$165 (the cost at the study institution) mesh reinforce-
ment will produce a cost saving if the probability of the occur-
rence of pancreatic leak is 52.7%. Two-way sensitivity analysis
demonstrated that mesh reinforcement would be expected to
provide cost savings over a clinically relevant range of values for
effectiveness and cost of mesh (Fig. 3). An analysis using data on
leakage rates in patients who were given mesh reinforcement
(Table 1) in the present clinical trial showed that mesh priced at
US$1804 would still result in a cost saving. Other sensitivity
analyses completed did not contraindicate the cost savings to be
obtained by the use of mesh reinforcement.
Discussion
Pancreatic leaks remain a clinically significant problem and as a
result impact on costs to the health care system. The present
authors and others have demonstrated that mesh reinforcement
of stapled pancreatectomy reduces the occurrence of clinically
significant leaks.8,12,13 The present study explored a simplified
decision model which looked at the major determinants of
health system costs and applied this to patients undergoing left
pancreatectomy with and without mesh reinforcement. Mesh
reinforcement resulted in an average cost benefit to the health
care system of US$2168 per patient. The present data were also
able to show that this benefit would be expected to be main-
tained over a clinically relevant range of leaks and mesh costs.
This cost saving was more modest than had been hoped, but
even modest health care savings can become substantial when
applied across the large number of patients who undergo left
pancreatectomy each year.
The present study should be interpreted in the light of several
limitations. Firstly, although the model is based on the results of
an RCT, not all of the data elements on resource use that are
required to obtain a true estimation of costs were captured. None-
theless, in the light of the superior clinical outcomes seen with
mesh reinforcement, it is likely that the inclusion of such costs
would have increased the extent of the cost savings derived in
patients who were given mesh reinforcement and would thus have
Table 2 List of costs
Factor Cost, US$ Description
Cost of surgery $11 850 Cost for surgery. Physician 48140; hospital DRG 192
Mesh reinforcement $165 Cost for mesh during surgery
Readmit patient $5248 Cost to readmit patient. No physician charge; hospital DRG 192
Install drain $433 Cost to install drain. Physician 43267; no hospital charge
Laboratory test $110 Cost to test for pancreatic leak
Replace drain $433 Assumed to be same as first installation
Drain management (no mesh) $30 (average: 35 days) Cost to maintain drain with no mesh
Drain management (with mesh) $30 (average: 17 days) Cost to maintain drain with mesh
DRG, diagnosis-related group code.
Figure 2 One-way sensitivity analysis: plot of expected values (i.e. costs) of treatment options across various probabilities of pancreatic
leaks
896 HPB
HPB 2013, 15, 893–898 © 2013 International Hepato-Pancreato-Biliary Association
strengthened the present findings. Secondly, it is important to
recognize that primary quality-of-life data were not collected
from trial participants. Lastly, it is typically recommended that
evaluations of health care programmes should be conducted from
the societal perspective, as well as from that of a cost–utility analy-
sis.14 Cost–utility analyses are not typically accepted in the USA
for making coverage decisions and therefore a cost–utility analysis
is unlikely to influence US decisionmakers.15 Conversely, payers in
Canada and the European Union typically require that the societal
perspective be taken along with a cost–utility analysis. However, it
must be noted that as the findings of the present study demon-
strate a positive net benefit from the payer’s perspective, an analy-
sis from the societal perspective would result in similar findings
because such an analysis would take a broader perspective of
benefit than that obtained from the payer’s perspective by apply-
ing societal willingness to pay for the benefit of the intervention.16
In addition, clinically significant leaks impact patients in very
diverse ways and thus it could be speculated that the avoidance of
leaks would result in an earlier return to work and earlier initia-
tion of chemotherapy in some patients.
Health care costs have escalated, often driven by innovation and
progress. It is increasingly important to look for innovations that
save health care dollars while benefiting patients. Therefore, it is
reasonable to utilize this study of cost benefit as further evidence
to justify the use of mesh reinforcement in left pancreatectomy.
Further innovations are needed to limit the impact of pancreatic
leak. Including cost benefit analyses in future study designs may
aid in selecting the best and most cost-effective options for
patients.
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